Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Molecular Diagnostics Market 2016 Share, Trend, Segmentation and Forecast to 2020

Wednesday, November 16, 2016 3:13
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Description

According to the new report by Rockville Research titled “Global Molecular Diagnostics Market – Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA) – Industry Outlook 2022”, there has been unprecedented rise in sexually infected diseases such as Chlamydia and Gonorrhea, particularly in the US. CT/NG is most prevalent sexually transmitted diseases (STD) in the US with consistent rise in the number of Chlamydia and Gonorrhea cases. The Government has also recommended regular screening for patients belonging to two of the major segments of the molecular diagnostics market: HPV and CT/NG.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685481-global-molecular-diagnostics-market-industry-outlook-2022

The report “Global Molecular Diagnostics Market – Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA) – Industry Outlook 2022” provides an in-depth analysis of global molecular diagnostics market which is estimated to be valued at US$ 30.99 billion in the year 2016 and projected to reach US$ 44.00 billion by 2020, growing at a CAGR of 9.3% in the period 2016-22. The report focuses on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA). The infectious diseases segment dominates the molecular diagnostics market by application with HPV dominating in virology segment and CT/NG in bacteriology segment. It provides details on current and forecasted scenario of each of aforementioned diseases.

Growth of the market is driven by prevalence of reproductive infectious diseases such as Chlamydia and Gonorrhea, surge in various types of oncology diagnostics, ageing population and government’s mandate on regular screening of HPV and CT/NG. However, growth of the industry is incumbent due to ambiguity in relation to reimbursement guidelines and presence of complex regulatory framework. Global Molecular Diagnostics market is dominated by few major companies, of which Roche Holding, Novartis AG, Hologic Inc., and Qiagen NV have been covered in the report.

1. Executive Summary
2. Research Methodology
3. Introduction
      3.1.1 History of Molecular Diagnostics
      3.1.2 Molecular Diagnostics vs. Conventional diagnostics
      3.1.3 Types of Molecular Diagnostics
4. Molecular Diagnostic Market
    4.1 Global Molecular Diagnostics Market Analysis
      4.1.1 Market Size by Value (Actual & Forecasted)
      4.2.1 Market Share by Segment
      4.2.2 Market Share by Discpline
      4.2.3 Market Share by Competitors
      4.2.4 Market Share by Region
5. Global Molecualr Diagnostics Market Segmentation
    5.1 Clinical Infectious Disease Segment
      5.1.1 Virology Segment – Human Papilloma virus (HPV) Testing Market
          5.1.1.1 Market Size by Value (Actual & Forecasted)
          5.1.1.2 Market Size by Volume (Actual & Forecasted)
          5.1.1.3 Market Share by Region (Actual & Forecasted)
          5.1.1.4 Market Share by Competitors
    5.2 Bacteriology – CT/NG Testing Market
      5.2.1 Market Size by Value (Actual & Forecasted)
      5.2.2 Market Size by Volume (Actual & Forecasted)
      5.2.3 Market Share by Region (Actual & Forecasted)
      5.2.4 Market Share by Competitors
    5.3 Genomics Testing Market – HLA Testing Market
      5.3.1 Market Size by Value (Actual & Forecasted)
      5.3.2 Human Leukocyte Antigen (HLA) Testing Market
    5.4 Blood Donor Screening Segment
6. Global Molecular Diagnostics Market Dynamics
    6.1 Market Trends & Developments
      6.1.1 Strategic Alliances
      6.1.2 Next Generation Sequencing in Clinical Molecular Diagnostics
    6.2 Growth Drivers
      6.2.1 Surge in Oncology Diagnostics
      6.2.2 Prevalence of Reproductive Infectious Disease
      6.2.3 Growing geriatric population
      6.2.4 Government’s mandate on regular screening of HPV and CT/NG
    6.3 Challenges
      6.3.1 Complex Regulatory Framework
      6.3.2 Lack of Clarity on Reimbursement
7. Competitive Landscape
8. Company Profiles
    8.1 Roche Holding AG
      8.1.1 Business Overview
      8.1.2 Financial Overview
      8.1.3 Business Strategies
    8.2 Novartis AG
      8.2.1 Business Overview
      8.2.2 Financial Overview
      8.2.3 Business Strategies
    8.3 Qiagen NV
      8.3.1 Business Overview
      8.3.2 Financial Overview
      8.3.3 Business Strategies
    8.4 Hologic Inc
      8.4.1 Business Overview
      8.4.2 Financial Overview
      8.4.3 Business Strategies

Get It Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685481

Contact US:                                                                                                   

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.